BDRX

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.0155
Percentage change -1.74	%

Peers: ATNM XNCR FATE GERN KPTI CYCC MRKR TGTX ONCT PSTV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-17.42	Insider Own	-	Shs Outstand	0.67M	Perf Week	1.79%
Market Cap	0.59M	Forward P/E	-	EPS next Y	-0.00	Insider Trans	-	Shs Float	-	Perf Month	-23.33%
Enterprise Value	-0.59M	PEG	-	EPS next Q	-0.00	Inst Own	25.03%	Short Float	-	Perf Quarter	-42.12%
Income	-7.31M	P/S	-	EPS this Y	59.49%	Inst Trans	0.17%	Short Ratio	0.08	Perf Half Y	-79.86%
Sales	0.00M	P/B	1.97	EPS next Y	75.05%	ROA	-45.75%	Short Interest	0.19M	Perf YTD	-78.42%
Book/sh	0.44	P/C	0.28	EPS next 5Y	-	ROE	-89.21%	52W High	41.50 -97.89%	Perf Year	-95.74%
Cash/sh	3.12	P/FCF	-	EPS past 3/5Y	90.74% 83.98%	ROIC	-69.15%	52W Low	0.78 11.39%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.19% 9.69%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	96.37%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.75	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	38.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.75	EPS Q/Q	87.43%	SMA20	-4.49%	Beta	0.98	Target Price	18.00
Payout	-	Debt/Eq	0.09	Sales Q/Q	-100.00%	SMA50	-21.83%	Rel Volume	0.07	Prev Close	0.89
Employees	13	LT Debt/Eq	0.01	Earnings	Apr 11 BMO	SMA200	-74.04%	Avg Volume	2.31M	Price	0.87
IPO	Dec 07, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	-16.67% -	Trades		Volume	153,764	Change	-1.74%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-08-24	Initiated	Ladenburg Thalmann	Buy	$8

Jun-27-25 08:30AM	Results of Annual General Meeting (GlobeNewswire) -6.21%
Jun-25-25 08:30AM	Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Jun-23-25 08:30AM	Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) (GlobeNewswire) +6.22%
Jun-18-25 07:00AM	Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study (ACCESSWIRE) +29.35%
Jun-11-25 04:30PM	Result of General Meeting (GlobeNewswire)
08:30AM	Loading…
Jun-04-25 08:30AM	Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes (GlobeNewswire)
May-31-25 08:40AM	Biodexa Pharmaceuticals sees cash runway into 1Q26 (TipRanks)
May-30-25 08:30AM	Shareholder Update (GlobeNewswire)
May-22-25 04:30PM	Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Notice of General Meeting (GlobeNewswire) +6.92% -17.27%
08:30AM	Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M (GlobeNewswire)
May-20-25 09:55AM	Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-12-25 08:30AM	Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP (GlobeNewswire) -12.77%
May-02-25 04:30PM	Result of General Meeting (GlobeNewswire)
Apr-24-25 12:00PM	What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock (Zacks) +9.86%
Apr-17-25 08:30AM	Notice of General Meeting (GlobeNewswire)
08:30AM	Loading…
Apr-11-25 08:30AM	Preliminary Results for the Year Ended 31 December 2024 (GlobeNewswire) +12.74%
Mar-19-25 07:00AM	With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter (ACCESSWIRE) +16.13%
Mar-10-25 08:30AM	Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP (GlobeNewswire) -6.56%
Mar-06-25 08:30AM	Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP (GlobeNewswire)
Feb-24-25 08:30AM	Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use (GlobeNewswire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-13-25 08:30AM	Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 (GlobeNewswire)
Feb-12-25 07:30AM	Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status (ACCESSWIRE)
Feb-10-25 08:30AM	Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis (GlobeNewswire) +31.94%
Jan-22-25 08:30AM	Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer (GlobeNewswire) -5.45%
Nov-22-24 08:30AM	Result of General Meeting (GlobeNewswire)
Nov-21-24 07:35AM	Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic (ACCESSWIRE) +14.29%
Nov-12-24 08:48AM	Biodexa Pharmaceuticals PLC ( Biodexa or the Company ) Regains Compliance For Continued Listing on Nasdaq (GlobeNewswire)
Nov-07-24 04:30PM	Notice of General Meeting (GlobeNewswire) -5.42%
Oct-17-24 07:30AM	Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer (ACCESSWIRE) -30.12%
04:15PM	Loading…
Oct-15-24 04:15PM	Biodexa Announces Successful Appeal of Nasdaq Delisting (GlobeNewswire) +67.66%
Oct-04-24 08:30AM	Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma (GlobeNewswire) -7.62%
Sep-26-24 08:30AM	Interim results for the six months ended June 30, 2024 (GlobeNewswire)
Sep-19-24 04:30PM	ADR Ratio Change (GlobeNewswire) -20.19%
Sep-16-24 08:30AM	Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant (GlobeNewswire)
Aug-30-24 04:30PM	Receipt of Nasdaq Delisting Determination - Plans to Appeal (GlobeNewswire) -17.25%
Jul-23-24 08:30AM	Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Jul-19-24 08:30AM	Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -14.94%
Jul-16-24 08:30AM	Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada (GlobeNewswire)
Jul-12-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-11-24 12:51PM	JOBY Stock Pops After Completing 523-Mile eVTOL Flight (InvestorPlace) +51.88%
12:31PM	KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains (InvestorPlace)
12:10PM	Why Is Biodexa Pharmaceuticals (BDRX) Up 56% Today? (InvestorPlace)
08:30AM	Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data (ACCESSWIRE)
Jul-02-24 08:30AM	Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 (GlobeNewswire)
Jun-24-24 08:30AM	Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa at 12 months in Familial Adenomatous Polyposis (FAP) (GlobeNewswire) -15.63%
Jun-13-24 09:35AM	Results of Annual General Meeting (GlobeNewswire)
Jun-10-24 08:30AM	Twelve month Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona (GlobeNewswire)
Jun-03-24 08:00AM	Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer (ACCESSWIRE) +10.95%
May-22-24 08:30AM	Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises (GlobeNewswire) -45.06%
May-21-24 08:30AM	Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting (GlobeNewswire) +83.46%
08:28AM	Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 78% Today? (InvestorPlace)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-15-24 03:58AM	Posting of Annual Report & Notice of AGM - Total Voting Rights (GlobeNewswire)
May-09-24 08:00AM	Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition (ACCESSWIRE)
Apr-30-24 11:52AM	Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting (GlobeNewswire) +15.27%
Apr-28-24 12:01PM	12 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-26-24 03:18PM	Why Is Biodexa (BDRX) Up 70% Today? (InvestorPlace) +79.36%
08:30AM	Biodexa Enters Into Exclusive License to eRapa , a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Apr-19-24 08:00AM	Preliminary Results for the Year Ended 31 December 2023 (GlobeNewswire) -8.30%
Mar-28-24 11:22AM	Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today? (InvestorPlace) +88.59%
08:15AM	Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers (ACCESSWIRE)
Mar-01-24 08:00AM	Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone (ACCESSWIRE) +7.09%
Feb-23-24 08:30AM	Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update (GlobeNewswire)
Feb-08-24 08:30AM	Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients (GlobeNewswire)
Feb-07-24 08:30AM	Biodexa Announces Allowance of U.S. Patent Covering Tolimidone (GlobeNewswire) -11.77%
Jan-22-24 08:30AM	Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024 (GlobeNewswire)
Dec-29-23 04:05AM	Biodexa Appoints Ann Merchant to the Board of Directors (GlobeNewswire)
Dec-21-23 04:00PM	Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option (GlobeNewswire)
Dec-19-23 08:42AM	Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering (GlobeNewswire) -12.54%
Nov-27-23 09:00AM	Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes (GlobeNewswire) +83.15%
Oct-03-23 08:30AM	Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma (GlobeNewswire)
Sep-29-23 04:30PM	Interim results for the six months ended 30 June 2023 (GlobeNewswire) -6.61%
Sep-21-23 08:30AM	Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO) (GlobeNewswire)
Jul-28-23 08:00AM	Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites (GlobeNewswire)
Jul-24-23 07:30AM	Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement (GlobeNewswire) +15.18%
Jul-10-23 08:00AM	Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs) (GlobeNewswire)
Jul-06-23 04:30PM	Results of Appeal of Delisting Determination (GlobeNewswire) -6.85%
08:15AM	Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) (GlobeNewswire)
Jun-22-23 04:15PM	ADR Ratio Change (GlobeNewswire) -15.19%
Jun-20-23 08:00AM	Appeal of Delisting Determination (GlobeNewswire) -12.11%
Jun-15-23 04:05PM	Receipt of NASDAQ Delisting Determination Plans to Appeal (GlobeNewswire) +15.68%
Jun-14-23 08:30AM	Results of Annual General Meeting and General Meeting (GlobeNewswire) -6.78%
May-26-23 04:05PM	Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering (GlobeNewswire)
May-24-23 08:40AM	Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering (GlobeNewswire) -32.38%
May-22-23 04:15PM	Posting of Annual Report & Notice of AGM (GlobeNewswire)
May-18-23 08:30AM	Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals (GlobeNewswire) -8.69%
Apr-28-23 04:30PM	Preliminary Results for the Year Ended 31 December 2022 (GlobeNewswire) -6.45%
Apr-20-23 01:30PM	Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity (ACCESSWIRE)
Apr-11-23 08:15AM	Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity (ACCESSWIRE) +6.49%
Apr-06-23 06:33AM	Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity (ACCESSWIRE) -10.32%
Apr-03-23 08:00AM	Biodexa Pharmaceuticals PLC Announces Issue of Pre-Funded Warrants (ACCESSWIRE) -23.08%
Mar-30-23 06:20AM	Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity (ACCESSWIRE) -11.24%

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Biodexa Pharmaceuticals Plc ADR

Upgrade your FINVIZ experience